Related Experiment Videos
Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing
C Lerman1, C Hughes, R T Croyle
1Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, 20007, USA. Lermanc@gunet.georgetown.edu
Preventive Medicine
|July 18, 2000
Summary
Most BRCA1/2 gene mutation carriers do not opt for prophylactic surgery and many do not follow recommended cancer surveillance. Improved risk communication and decision-making support are needed for hereditary breast cancer management.
Area of Science:
- Genetics
- Oncology
- Behavioral Science
Background:
- Genetic testing for breast cancer risk (BRCA1/2) is available but its effect on patient behavior is not well understood.
- This study investigated prophylactic surgery and surveillance practices in the year after genetic testing.
Purpose of the Study:
- To assess the uptake of prophylactic surgery and adherence to surveillance protocols among women undergoing BRCA1/2 genetic testing.
- To identify factors influencing these health-related behaviors in hereditary breast cancer families.
Main Methods:
- A prospective observational study of 216 female participants from hereditary breast-ovarian cancer families (carriers, noncarriers, test decliners).
- Assessment of prophylactic surgery utilization and surveillance behavior (mammography, CA125, transvaginal ultrasound) one year post-BRCA1/2 testing.
Main Results:
- Only 3% of unaffected carriers underwent prophylactic mastectomy; 13% had prophylactic oophorectomy.
- Mammography rates were higher in carriers (68%) versus noncarriers (44%), but this reflected decreased screening in noncarriers.
- Adherence to surveillance remained unchanged from baseline for carriers; younger women (25-39) were less likely to obtain mammograms.
Conclusions:
- A significant proportion of BRCA1/2 carriers do not choose prophylactic surgery or adhere to recommended surveillance guidelines.
- Enhanced risk communication and shared medical decision-making are crucial for optimizing care in hereditary cancer syndromes.